Skip to main content

HLA DR15 (DR2) Immunosuppressive Response Association in Myelodysplastic Syndrome (MDS)

CPT

81377

Synonyms
  • DR15
  • Immunosuppressive Response
  • MDS
  • Myelodysplastic Syndrome
  • Share
  • Print
  • Updated on 04/14/2025

Test Details

Methodology

HLA results are obtained using Next Generation Sequencing (NGS). This is reported as a Class II antigen level assay.

Polymerase chain reaction (PCR)/sequence-specific oligonucleotide probes (SSOP)

This is a class II antigen level test.

HLA results are obtained using Next Generation Sequencing (NGS). This is reported as a Class II antigen level assay.

Result Turnaround Time

3 - 7 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Use

This test is used to determine the presence of DR15 antigen.

Determine the presence of DR15 antigen.

This test is used to determine the presence of DR15 antigen.

Special Instructions

When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. Please call 800-533-1037 (HLA customer service) to obtain the buccal swab kit or for assistance in selecting the proper HLA test for the patient.

Limitations

Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for testing.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for testing.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).

Even with appropriate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for testing.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

References

Clinical Practice Guidelines in Oncology. Version 3. Fort Washington, Pa: National Comprehensive Cancer Network (NCCN); 2006.
Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002 Sep 1; 100(5):1570-1574. 12176872

Specimen Requirements

Specimen

Whole blood or buccal swabs

Volume

7 mL whole blood or four buccal swabs

Minimum Volume

3 mL whole blood or four buccal swabs

Container

Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal swab kit, please telephone 800-533-1037.

Storage Instructions

Maintain blood specimen at room temperature. Keep buccal swabs dry and at room temperature.

Causes for Rejection

Hemolysis; clotted specimen; insufficient amount of DNA on buccal swabs; yellow-top (ACD) tube

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
167100 HLA DR15 167101 HLA DR15 6803-1
167100 HLA DR15 167384 HLA Methodology 49549-9
Order Code167100
Order Code NameHLA DR15
Order Loinc
Result Code167101
Result Code NameHLA DR15
UofM
Result LOINC6803-1
Order Code167100
Order Code NameHLA DR15
Order Loinc
Result Code167384
Result Code NameHLA Methodology
UofM
Result LOINC49549-9